Shire announces collaboration over possible new therapy

Shire has revealed it is collaborating with US biotech firm NanoMedSyn on the development of a potential enzyme replacement therapy (ERT), which may be used to treat a Lysosomal storage disorder.

The exact identity of the disorder that the new ERT may treat has not been revealed, but this may be revealed in due course if the evaluation work to be carried out by NanoMedSyn confirms the effectiveness of the treatment. 

NanoMedSyn's proprietary synthetic derivatives, known as AMFA, wll be used to carry out the preclinical research. 

The firms stated that AMFA has a strong affinity for binding to the mannose 6-phosphate (M6P) receptor, which is a major trafficking pathway for a Lyposomal condition.

Shire’s chief executive and head of research and development Andreas Busch said: “The novel design of AMFA and the promising biological activity demonstrated in preclinical models makes this program an exciting opportunity for Shire to further expand its commitment to evaluating potential advancements in lysosomal storage disorder treatments."

Lysosomal storage disorders are metabolic in nature and are caused by enzyme deficiencies that lead to an excessive accumulation of toxins in the body's cells.
 
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.